Senseonics stock gains 3.13 percent as targets stay higher than price!234!?

Published on 10/05/2026 at 20:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Senseonics stock trades at USD 10.19 on October 5, 2026, while six analysts set a Moderate Buy consensus and a USD 17.20 average target. Q2 revenue reached USD 14.48 million.

SENS, US81727U3032, Illustration mit AI erstellt.

Senseonics stock (ISIN US81727U3032) was trading at USD 10.19 on Nasdaq on October 5, 2026, up 3.13 percent from the prior close. The move puts the share price at 88.0 percent of its 52-week high of USD 11.58, while the medical-device company approaches its next reported checkpoint in November.

MarketBeat reported on October 1, 2026, that six analysts held a Moderate Buy consensus on Senseonics, with four Buy ratings, one Hold and one Sell. The average 12-month price target was USD 17.20, which places the target 68.8 percent above the October 5 trading price, according to MarketBeat.

Beta Bionics integration targets Q4

Senseonics announced on September 14, 2026, that it would integrate its Eversense 365 continuous glucose monitor with Beta Bionics' iLet Bionic Pancreas. GlobeNewswire reported that development is expected to finish in the fourth quarter, with commercial launch planned after testing, validation and regulatory requirements.

The partnership gives Senseonics a route into an automated insulin-delivery system while keeping the one-year implantable Eversense 365 at the center of the product strategy. The launch timing is therefore a concrete operating milestone, but the release also identifies testing, validation and regulatory work as conditions before commercialization.

Revenue growth meets deeper losses

For the quarter ended June 30, 2026, Senseonics generated USD 14.48 million in revenue, compared with USD 6.65 million in the same quarter of 2025. That is a calculated increase of 117.7 percent, while GAAP net loss widened to USD 36.71 million from USD 14.50 million, according to Markets Insider.

Diluted EPS was negative USD 0.63 versus a consensus loss of USD 0.55, a miss of USD 0.08 per share. At the same time, Senseonics raised full-year 2026 revenue guidance to USD 62 million to USD 66 million from USD 60 million to USD 64 million, as reported by GlobeNewswire.

Stock remains below yearly high

The Nasdaq share price was trading at USD 10.19 at 2:18 p.m. ET on October 5, 2026. The session range was USD 9.59 to USD 10.31, volume was 348,248 shares and market capitalization was USD 425.9 million.

The next earnings report is scheduled for November 10, 2026, according to Investing.com. For investors, the central tension is visible in the numbers: revenue more than doubled year over year, while the latest quarterly loss remained materially larger than the prior-year loss.